Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 16, 2016 - Issue 2
Submit an article Journal homepage
249
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C

Vicente Gimeno-BallesterHospital Universitario Miguel Servet-Pharmacy Department, Isabel la Católica 1–3, Zaragoza, Zaragoza 50009, Spain;Faculty of Pharmacy, University of Granada, Granada, SpainCorrespondence[email protected]
,
Javier MarHospital Alto Deba-Clinical Management Service, Mondragón, Spain
&
Ramón San MiguelComplejo Hospitalario de Navarra-Pharmacy Department, Pamplona, Spain;Faculty of Pharmacy, University of Granada, Granada, Spain
Pages 285-294 | Published online: 29 Aug 2015

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jaume Puig-Junoy, Natàlia Pascual-Argente, Lluc Puig-Codina, Laura Planellas & Míriam Solozabal. (2018) Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Review of Gastroenterology & Hepatology 12:12, pages 1251-1263.
Read now

Articles from other publishers (10)

László Szilberhorn, Zoltán Kaló & Tamás Ágh. (2018) Cost-Effectiveness of Second-generation Direct-acting Antiviral Agents in Chronic HCV Infection: A Systematic Literature Review. Antiviral Therapy 24:4, pages 247-259.
Crossref
Kathrin Krüger, Christian Krauth, Siegbert Rossol, Stefan Mauss, Klaus H.W. Boeker, Tobias Müller, Hartwig Klinker, Anita Pathil, Renate Heyne & Jona T. Stahmeyer. (2019) Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. European Journal of Gastroenterology & Hepatology 31:2, pages 230-240.
Crossref
Rodolfo Castro, Louise Crathorne, Hugo Perazzo, Julio Silva, Chris Cooper, Jo Varley-Campbell, Daniel Savignon Marinho, Marcela Haasova, Valdilea G. Veloso, Rob Anderson & Chris Hyde. (2018) Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Medical Research Methodology 18:1.
Crossref
Gabriel Tremblay, Daniel Howard, Wan Tsong, Vardhaman Patel & Jesús De Rosendo. (2018) Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective. Epilepsy & Behavior 86, pages 108-115.
Crossref
Lauren E. Cipriano & Jeremy D. Goldhaber-Fiebert. (2018) Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy & Practice 3:1, pages 238146831877663.
Crossref
X. Li, N. S. Chan, A. W. Tam, I. F. N. Hung & E. W. Chan. (2017) Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. European Journal of Clinical Microbiology & Infectious Diseases 36:10, pages 1801-1809.
Crossref
Juan Turnes, Raquel Domínguez-Hernández & Miguel Ángel Casado. (2017) Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. Gastroenterología y Hepatología 40:7, pages 433-446.
Crossref
Juan Turnes, Raquel Domínguez-Hernández & Miguel Ángel Casado. (2017) Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. Gastroenterología y Hepatología (English Edition) 40:7, pages 433-446.
Crossref
Roberto Nuño Solinís, Patricia Arratibel Ugarte, Ander Rojo & Yuri Sanchez Gonzalez. (2016) Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infectious Diseases and Therapy 5:4, pages 491-508.
Crossref
Jagpreet Chhatwal, Tianhua He & Maria A. Lopez-Olivo. (2016) Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. PharmacoEconomics 34:6, pages 551-567.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.